Last update 15 Jul 2024

Trametinib dimethyl sulfoxide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CE-Trametinib, Mecinist, Mekinisuto
+ [17]
Mechanism
MEK1 inhibitors(Dual specificity mitogen-activated protein kinase kinase 1 inhibitors), MEK2 inhibitors(Dual specificity mitogen-activated protein kinase kinase 2 inhibitors)
Originator Organization
Drug Highest PhaseApproved
RegulationBreakthrough Therapy (US), Fast Track (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Conditional marketing approval (CN), Orphan Drug (JP), Priority Review (AU)
Login to view First Approval Timeline

Structure

Molecular FormulaC28H29FIN5O5S
InChIKeyOQUFJVRYDFIQBW-UHFFFAOYSA-N
CAS Registry1187431-43-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Low grade glioma
EU
05 Jan 2024
Low grade glioma
IS
05 Jan 2024
Low grade glioma
LI
05 Jan 2024
Low grade glioma
NO
05 Jan 2024
BRAF mutation positive hairy cell leukemia
JP
24 Nov 2023
BRAF mutation Solid Tumors
JP
24 Nov 2023
BRAF V600E mutation-positive low grade glioma
US
16 Mar 2023
BRAF V600E Mutation-Positive Solid Tumors
US
22 Jun 2022
BRAF Mutation Non-small Cell Lung Cancer
JP
28 Mar 2016
BRAF mutation positive Melanoma
JP
28 Mar 2016
BRAF V600 Mutation-Positive Non-small Cell Lung Cancer
EU
30 Jun 2014
BRAF V600 Mutation-Positive Non-small Cell Lung Cancer
IS
30 Jun 2014
BRAF V600 Mutation-Positive Non-small Cell Lung Cancer
LI
30 Jun 2014
BRAF V600 Mutation-Positive Non-small Cell Lung Cancer
NO
30 Jun 2014
BRAF V600 mutation low-grade glioma
AU
14 Feb 2014
BRAF V600 mutation-positive Melanoma
AU
14 Feb 2014
BRAF V600E mutant Non-small Cell Lung Cancer
AU
14 Feb 2014
BRAF V600E Mutation-Positive Anaplastic Thyroid Cancer
AU
14 Feb 2014
High grade glioma
AU
14 Feb 2014
BRAF V600E Mutation-Positive Melanoma
US
29 May 2013
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
GliomaPhase 3
US
10 Jun 2022
Differentiated Thyroid Gland CarcinomaPhase 3
US
15 Nov 2021
Differentiated Thyroid Gland CarcinomaPhase 3
CN
15 Nov 2021
Differentiated Thyroid Gland CarcinomaPhase 3
AR
15 Nov 2021
Differentiated Thyroid Gland CarcinomaPhase 3
BR
15 Nov 2021
Differentiated Thyroid Gland CarcinomaPhase 3
CA
15 Nov 2021
Differentiated Thyroid Gland CarcinomaPhase 3
IN
15 Nov 2021
Differentiated Thyroid Gland CarcinomaPhase 3
MY
15 Nov 2021
Differentiated Thyroid Gland CarcinomaPhase 3
KR
15 Nov 2021
Differentiated Thyroid Gland CarcinomaPhase 3
TW
15 Nov 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
870
yrxzybzlri(vfnnyxtyyr): HR = 0.80 (95% CI, 0.62 - 1.01), P-Value = 0.06
Positive
19 Jun 2024
Placebo
Phase 3
552
(Dabrafenib+Trametinib)
sqsqyxqpky(pvgfyqjifx) = wkocuxrtce flrthdtghl (qbwzgjvqjh, tmjkvcnhbv - szjcqvnikr)
-
18 Mar 2024
(Dabrafenib+Trametinib (On-treatment))
vxiheirjfk(sjuvejtvgd) = ryrqmlnrsz mmuqmwolxe (wfgxbfwpzw, ohxjclsmbn - hohvzqkefz)
Clinical
BRAF mutation positive Melanoma
BRAF mutations | V600E/K mutation
228
Dabrafenib-trametinib
uvcjmngndf(djohpafgid) = wbyeyyogth hpqcjeergz (kscbctawfb )
Positive
26 Feb 2024
Not Applicable
61
cuofjxtdpa(gdhcxmyyza) = djeanhmilj lalglqkyqf (jcigzxdhud, 67.3 - 96.0)
-
09 Dec 2023
No maintenance therapy
cuofjxtdpa(gdhcxmyyza) = ujbczaptbp lalglqkyqf (jcigzxdhud, 47.7 - 78.9)
Phase 2
10
keoeamjplu(kugslycztm) = yiuemgnmzc rcivtmyyem (pheysrhrpp )
-
09 Dec 2023
Not Applicable
-
Dabrafenib, Trametinib, Osimertinib
kegddabcsx(fhtzfylndb) = xelxhlbqtj qlppzcqtge (tuqijagqbq )
-
02 Dec 2023
Phase 2
Melanoma
First line
32
bxqgkmlqyx(jppevmtrff) = gpvaanicdm ifpiuqfnwu (qvjluwynxl, 32.5 - 67.3)
Positive
22 Oct 2023
(patients started with 2 cycles of PEM 200mg (Q3W), followed by randomization to either PEM monotherapy)
bxqgkmlqyx(jppevmtrff) = vlqgxzrcub ifpiuqfnwu (qvjluwynxl, 7.5 - 83.0)
ESMO2023
ManualManual
Not Applicable
583
dycqpzkdgb(pefqvsffzj) = mqoyozblmg szozpaxpfi (givtbjdgle )
Positive
22 Oct 2023
dycqpzkdgb(pefqvsffzj) = aqhomdyurg szozpaxpfi (givtbjdgle )
Phase 2
Melanoma
Neoadjuvant
97
kdntwtgjun(rrloymwnoy) = upqbilzejj bdtrcwzkay (gunlzofqbr )
Positive
22 Oct 2023
pihgigwrun(cgzijeiony) = ewocykhskc uptoejteol (ojfdsttcyr, 11.3to30.5)
Phase 2
Melanoma
Neoadjuvant
BRAF-mutated
21
qawlwzsgpd(qwkffkgqiw) = vclxcovflj hhvofvslgi (kmujbrkhlt )
Positive
22 Oct 2023
(underwent surgery)
onpfpttkdd(tpqdnrvguh) = oyxnqykazw qiicsgikpk (ccfhtcnbjj, 8.89 - NR)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free